Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bavisant
- Development stage
- Phase 2
- Lead developer
- BenevolentAI
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bavisant is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. It was originally developed by Johnson & Johnson for the treatment of attention-deficit hyperactivity disorder (ADHD), but clinical trials did not demonstrate significant efficacy in adults with ADHD. Bavisant has also been investigated for other indications such as excessive daytime sleepiness in Parkinson’s disease and alcoholism. Its mechanism involves antagonism of the histamine H3 receptor, which modulates neurotransmitter release and is implicated in wakefulness and cognition[1][2][3][4][5][6].
- Other names
- bavisant dihydrochloride
02
Targets
HRH3 (Histamine Receptor H3)
Beyond the preview
Go deeper on bavisant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bavisant.